|Targets||Polo-like Kinase (PLK)|
|Description||Rigosertib, a synthetic benzyl styryl sulfone, is a non-ATP-competitive inhibitor of PLK1 (IC50=9 nM).|
|Synonyms||UNII-67DOW7F9GL;2-[2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]anilino]acetic acid;ON-01910; ON 01910; ON01910|
|Solubility||Soluble in DMSO|
|Storage||Store at -20 °C|
|Application||A non-ATP-competitive inhibitor of PLK1|
|Quality Standard||Enterprise Standard|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
|Current Developer||Onconova Therapeutics|
BI 6727 (Volasertib) is a small highly potent Polo-like kinase inhibitor (Plk) with an IC50 of 0 .87 nM and EC50 of 11-37 nM on a panel of cancer cell lines, w...
Rigosertib (ON-01910 sodium salt), a synthetic benzyl styryl sulfone analogue with potential antineoplastic activity, is a non-ATP-competitive inhibitor of PLK1...
CFI-400945, has been found to be a PLK4 inhibitor that could be probably useful in anticancer studies through influencing mitosis and inducing apoptosis. It is ...
Centrinone, a pyrimidinamine derivative, has been found to be a high affinity and selective PLK4 inhibitor (Ki = 0.16 nM).
The hydrochloride salt form of TAK-960, a newly studied selective PLK1 inhibitor, might have potential effect in inhibiting proliferation of sorts of cancer cel...
TAK-960 is an orally available, potent and selective PLK1 inhibitor that was in a phase I clinical trial in patients with advanced non-hematologic malignancies.
TC-S 7005 is a potent and selective polo-like kinase 2 (PLK2) inhibitor (IC50 = 4 nM) with selectivity over PLK3 and PLK1 (IC50 = 24 and 214 nM, respectively). ...
SBE13 is a cell-permeable highly potent polo-like kinase (Plk1) inhibitor that targets the inactive conformation of the kinase. Its IC50 value is 0.2 nM. It doe...